Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories

ABSTRACT: Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories

PROVIDER: PRJNA646874 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories [ChIP-Seq]

Project description:Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories [ChIP-Seq]

| PRJNA646876 | ENA

Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories [RNA-Seq]

Project description:Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories [RNA-Seq]

| PRJNA646877 | ENA

Different mutant RUNX1 oncoprotein classes program alternate haematopoietic differentiation trajectories [ChIP-seq2]

Project description:Different mutant RUNX1 oncoprotein classes program alternate haematopoietic differentiation trajectories [ChIP-seq2]

| PRJNA647754 | ENA

Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories [ATAC-Seq]

Project description:Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories [ATAC-Seq]

| PRJNA646875 | ENA

Different mutant RUNX1 oncoprotein classes program alternate haematopoietic differentiation trajectories [ChIP-seq2]

Project description:Mutations of the hematopoietic master regulator RUNX1 cause acute myeloid leukaemia, familial platelet disorder and other haematological malignancies whose phenotypes and prognoses depend on the class of RUNX1 mutation. The biochemical behaviour of these oncoproteins and their ability to cause unique diseases has been well studied but the genomic basis of their differential action is unknown. To address this question we compared integrated phenotypic, transcriptomic and genomic data from cells expressing four types of RUNX1 oncoproteins in an inducible fashion during blood development from embryonic stem cells. We show that each class of RUNX1 mutation rapidly deregulates endogenous RUNX1 function by different mechanisms, leading to specific alterations in developmentally controlled transcription factor binding and chromatin programming. The result are distinct perturbations in the trajectories of gene regulatory network changes underlying blood cell development that are consistent with the nature of the final disease phenotype. The development of novel treatments for RUNX1-driven diseases will therefore require consideration beyond RUNX1 haploinsufficiency.

2020-12-14 | GSE154858 | GEO

Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories [RNA-Seq]

2020-12-14 | GSE154622 | GEO

Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories [ChIP-Seq]

Project description:Mutations of the hematopoietic master regulator RUNX1 cause acute myeloid leukaemia, familial platelet disorder and other haematological malignancies whose phenotypes and prognoses depend on the class of RUNX1 mutation. The biochemical behavior of these oncoproteins and their ability to cause unique diseases has been well studied but the genomic basis of their differential action is unknown. To address this question we compared integrated phenotypic, transcriptomic and genomic data from cells expressing four types of RUNX1 oncoproteins in an inducible fashion during blood development from embryonic stem cells. We show that each class of RUNX1 mutation rapidly deregulates endogenous RUNX1 function by different mechanisms, leading to specific alterations in developmentally controlled transcription factor binding and chromatin programming. The result are distinct perturbations in the trajectories of gene regulatory network changes underlying blood cell development that are consistent with the nature of the final disease phenotype. The development of novel treatments for RUNX1-driven diseases will therefore require consideration beyond RUNX1 haploinsufficiency.

2020-12-14 | GSE154621 | GEO

Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories [ATAC-Seq]

Project description:Mutations of the hematopoietic master regulator RUNX1 cause acute myeloid leukaemia, familial platelet disorder and other haematological malignancies whose phenotypes and prognoses depend on the class of RUNX1 mutation. The biochemical behavior of these oncoproteins and their ability to cause unique diseases has been well studied but the genomic basis of their differential action is unknown. To address this question we compared integrated phenotypic, transcriptomic and genomic data from cells expressing four types of RUNX1 oncoproteins in an inducible fashion during blood development from embryonic stem cells. We show that each class of RUNX1 mutation rapidly deregulates endogenous RUNX1 function by different mechanisms, leading to specific alterations in developmentally controlled transcription factor binding and chromatin programming. The result are distinct perturbations in the trajectories of gene regulatory network changes underlying blood cell development that are consistent with the nature of the final disease phenotype. The development of novel treatments for RUNX1-driven diseases will therefore require consideration beyond RUNX1 haploinsufficiency.

2020-12-14 | GSE154620 | GEO

Different mutant RUNX1 oncoprotein classes program alternate hematopoietic differentiation trajectories

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-12-14 | GSE154623 | GEO

Different mutant RUNX1 oncoproteins program alternate haematopoietic differentiation trajectories.

Project description:Mutations of the haematopoietic master regulator RUNX1 are associated with acute myeloid leukaemia, familial platelet disorder and other haematological malignancies whose phenotypes and prognoses depend upon the class of the RUNX1 mutation. The biochemical behaviour of these oncoproteins and their ability to cause unique diseases has been well studied, but the genomic basis of their differential action is unknown. To address this question we compared integrated phenotypic, transcriptomic, and genomic data from cells expressing four types of RUNX1 oncoproteins in an inducible fashion during blood development from embryonic stem cells. We show that each class of mutant RUNX1 deregulates endogenous RUNX1 function by a different mechanism, leading to specific alterations in developmentally controlled transcription factor binding and chromatin programming. The result is distinct perturbations in the trajectories of gene regulatory network changes underlying blood cell development which are consistent with the nature of the final disease phenotype. The development of novel treatments for RUNX1-driven diseases will therefore require individual consideration.

| S-EPMC7812315 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data